B-HT 920 - CAS# 36085-73-1 Size:Solid 2 mg Inhibition of this enzyme's activity

Inhibition of this enzyme's activity by azoles results in decreased amounts of ergosterol

thereby preventing the binding of the MDM2 protein to the transcriptional activation domain of the tumor suppressor protein p53

Effect of Orexin A antagonist (SB-334867) infusion into the nucleus accumbens on consummatory behavior and alcohol preference in Wistar rats

Regio- and stereoselective synthesis of aminoinositols and 1

inhibited cell proliferation (IC50 = 31-125 nM) primarily in a cytostatic manner in cell lines that overexpress EGF-R or c-erbB-2

B-HT 920 - CAS# 36085-73-1 Size:Solid 2 mg Inhibition of this enzyme's activityTalipexole, also known as B HT920 and Domnin, is a dopamine agonist that is marketed as a treatment for Parkinson's Disease in Japan by Boehringer Ingelheim; it was introduced in 1996. As of December 2014 it was not approved for marketing in the US nor in Europe. Talipexole is a D2 dopamine receptor agonist and interacts both pre and post synaptic receptors. It also is an 2 adrenergic agonist. The main side effects are drowsiness, dizziness,